ADHD Trial, Recruiting NCT07162831 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT07162831
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The participant (and/or a parent or legal guardian) must have signed a consent form agreeing to take part
  • Children and young people aged 8 to 16 years old
  • People who have been diagnosed with ADHD, whether mild, moderate, or severe
  • People with an IQ score above 85, as measured by a specific intelligence test (WISC-V short form)
  • People who speak German or French
  • People who are willing to attend study visits without taking their ADHD medication

Who may not be able to join:

  • People who have an unstable neurological condition (such as epilepsy) that significantly affects their development
  • People who have a severe psychiatric condition (such as an eating disorder) or a severe learning disability that significantly affects their development
  • People where there are known or suspected concerns about whether they would follow the study requirements
  • People who would have difficulty following the study procedures, for example due to language barriers
  • The researchers running the trial, along with their family members, employees, or anyone else who depends on them, are not eligible to enrol

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Regula Everts, Prof. Dr. phil., Division of Neuropaediatrics, Development and Rehabilitation, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

Phone: +41 31 632 84 97

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
31 August 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Junior Metacognitive Awareness Inventory (Jr.MAI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov